Interleukin-23 (IL-23) is an upstream messenger in psoriasis. It keeps a particular set of immune cells alive and switched on, and those cells produce IL-17, which drives skin cells to multiply too fast and pulls inflammation into the skin. The result is a thick, red, scaly plaque.
Guselkumab is a lab-made antibody that binds the p19 subunit of IL-23 and neutralizes it. Removing the upstream signal lets the downstream machinery wind down.
Because it works upstream, the effect takes longer to build than with a drug that blocks IL-17 at the end of the chain — but it goes deeper and holds longer, which is why a single injection covers eight weeks. It also means guselkumab does not interfere with the specific IL-17 defenses against yeast, so the thrush and yeast infections associated with Cosentyx are not a feature of this drug. And unlike IL-17 blockers, it does not worsen inflammatory bowel disease — it treats it.
Live vaccines. No MMR, varicella, yellow fever, live nasal flu spray or oral typhoid while you are on Tremfya. Complete any of these before starting. Non-live vaccines — inactivated flu, COVID, pneumococcal, Shingrix — are fine and recommended.
Other biologics and JAK inhibitors. Do not stack immune-suppressing therapies.
Guselkumab is cleared like a protein rather than through liver enzymes, so there are no meaningful drug-drug interactions of the usual kind. Alcohol does not interact with it, and there is no special sun precaution beyond sensible everyday sun care.
Liver enzymes and bilirubin are checked at baseline if clinically indicated for psoriasis or psoriatic arthritis; they are required for the ulcerative colitis and Crohn's disease indications.
IL-23 blockers build gradually and then stay. Expect plaques to start thinning by around 4 weeks, meaningful clearing by 8 to 12 weeks, and your best result around 16 weeks — about when your third injection is due.
Do not judge it before 16 weeks. If you are still clearly flaring at that point on the full schedule, that is a fair moment to discuss a switch.
Scalp psoriasis tends to follow the body, sometimes a little behind. Nail psoriasis takes six months to a year, because the nail has to grow out — this is a limitation of nails, not of the drug.
Psoriatic arthritis joints usually improve over the first two to three months. IL-23 blockers are generally stronger on skin than on joints; if your arthritis is the bigger problem, say so early so the plan can reflect that.
The response tends to be durable. People who get clear on guselkumab often stay clear for years rather than slowly slipping.
Tremfya controls psoriasis. It does not cure it.
The drug clears from your body slowly, so nothing happens immediately when you stop. Most people go a couple of months or more before plaques begin returning, and it comes back gradually rather than as a rebound. It generally returns to about the severity you had before starting, not worse.
If you restart later, guselkumab usually still works. Antibodies that meaningfully block the drug are uncommon.
If you have to pause for an infection or surgery, that is routine and generally fine — restart once things have settled, in coordination with your dermatologist.
If you stop because it is not working, the usual next steps are the other IL-23 blocker Skyrizi, an IL-17 blocker like Cosentyx, or the oral drug Sotyktu.